🎯 check AG-221 (Enasidenib) product page
AG-221 (Enasidenib) is a potent, orally available, and selective mutant IDH2 inhibitor. It affects metabolic and epigenetic signaling pathways by reducing 2-HG production and promoting histone demethylation, effectively inducing cell differentiation and inhibiting tumor viability.